Cytek Biosciences, Inc.CTKBNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank48
3Y CAGR-26.9%
5Y CAGR-27.0%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-26.9%/yr
Quarterly compound
5Y CAGR
-27.0%/yr
Consistent
Percentile
P48
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 6.23% |
| Q3 2025 | 8.27% |
| Q2 2025 | 1.02% |
| Q1 2025 | 21.31% |
| Q4 2024 | -10.39% |
| Q3 2024 | -2.47% |
| Q2 2024 | 0.05% |
| Q1 2024 | 7.33% |
| Q4 2023 | -0.49% |
| Q3 2023 | -10.84% |
| Q2 2023 | 8.30% |
| Q1 2023 | 18.85% |
| Q4 2022 | 15.97% |
| Q3 2022 | -0.96% |
| Q2 2022 | 17.28% |
| Q1 2022 | -4.82% |
| Q4 2021 | 23.91% |
| Q3 2021 | 26.30% |
| Q2 2021 | 17.92% |
| Q1 2021 | 14.91% |
| Q4 2020 | 30.01% |
| Q3 2020 | -0.77% |
| Q2 2020 | -8.19% |
| Q1 2020 | 0.00% |